Bergan R C, Walls R G, Figg W D, Dawson N A, Headlee D, Tompkins A, Steinberg S M, Reed E
Department of Cell and Cancer Biology, National Cancer Institute, Bethesda, Maryland, USA.
J Natl Med Assoc. 1997 Sep;89(9):622-8.
African-American males have a higher incidence of prostate cancer than non-African-American males and an overall poorer prognosis. Environmental factors such as socioeconomic status and biological factors such as an increased frequency of androgen receptor mutation have been identified as causal. As androgen ablation therapy is ubiquitous in the treatment of metastatic prostate cancer, little information is available on clinical outcome independent of hormone therapy. Our experience at the Warren G. Magnusson Clinical Center, National Institutes of Health with the anticancer agent, suramin, offers the opportunity to study clinical outcome in patients treated with an agent whose tumoricidal activity is not dependent on androgen receptor function. Clinical outcome was examined retrospectively in 43 patients treated on a single suramin-based protocol and evaluated as a function of ethnic background. No significant difference in time to disease progression or survival was observed between African Americans (n = 4) and the other 39 patients. These findings are consistent with the hypothesis that therapies that work through mechanisms independent of the androgen receptor may result in similar outcomes across ethnic groups.
非裔美国男性患前列腺癌的几率高于非非裔美国男性，且总体预后更差。社会经济地位等环境因素以及雄激素受体突变频率增加等生物学因素已被确定为病因。由于雄激素剥夺疗法在转移性前列腺癌的治疗中普遍使用，因此关于独立于激素疗法的临床结果的信息很少。我们在美国国立卫生研究院沃伦·G·马格努森临床中心使用抗癌药物苏拉明的经验，为研究用一种杀肿瘤活性不依赖雄激素受体功能的药物治疗的患者的临床结果提供了机会。对43例接受单一基于苏拉明方案治疗的患者的临床结果进行了回顾性检查，并根据种族背景进行了评估。非裔美国人（n = 4）与其他39例患者在疾病进展时间或生存率方面未观察到显著差异。这些发现与以下假设一致，即通过独立于雄激素受体的机制起作用的疗法可能在不同种族群体中产生相似的结果。
